ARTICLE | Company News
FDA panel to review Gliadel
December 5, 2001 8:00 AM UTC
The FDA's Oncologic Drugs Advisory Committee is scheduled to review on Thursday an sNDA from Guilford (GLFD) to extend the label for its Gliadel to first-line therapy to treat malignant glioma. The me...